Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study

Clostridium difficile infection (CDI) has been primarily treated with metronidazole or vancomycin. High recurrence rates, the emergence of epidemic PCR ribotypes (RTs) and the introduction of fidaxomicin in Europe in 2011 necessitate surveillance of antimicrobial resistance and CDI epidemiology. The...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical microbiology & infectious diseases 2020-01, Vol.39 (1), p.169-177
Hauptverfasser:	Freeman, Jane, Vernon, Jonathan, Pilling, Sally, Morris, Kirsti, Nicolson, Scott, Shearman, Sharie, Clark, Emma, Palacios-Fabrega, Jose Alejandro, Wilcox, Mark
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Bacterial Agents - pharmacology Antiinfectives and antibacterials Antimicrobial agents Antimicrobial resistance Biomedical and Life Sciences Biomedicine Chloramphenicol Chloromycetin Clindamycin Clostridioides difficile - classification Clostridioides difficile - drug effects Clostridium difficile Clostridium Infections - epidemiology Drug resistance Enterocolitis, Pseudomembranous - epidemiology Epidemics Epidemiological Monitoring Epidemiology Europe - epidemiology Feces - microbiology Geographical distribution Humans Imipenem Internal Medicine Longitudinal Studies Medical Microbiology Metronidazole Microbial Sensitivity Tests Minimum inhibitory concentration Moxifloxacin Original Original Article Prevalence Ribotyping Rifampin Surveillance Tigecycline Toxins Vancomycin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!